Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0696

+1.6%

Nov 5 3:22 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

Jack Russell

From: Mammon	6/4/2014 9:14:37 AM
	1 Recommendation Read Replies (1) of 13111

The following article, given the obvious analogies between T-vec and pv10, shows the compelling promise of pv10, and why there is cause for much hope. Once we see pv10 in a combination trial with a PD-1 drug we will be on our way again. I also believe that the reason three execs from big pharmas joined the Strategic Advisory Board in the past two months was emerging trial results from the combinations of immunology drugs, and not because of the BTD. onclive.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next